Home › Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW
 

Keywords :   


Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

2015-05-19 09:30:24| Biotech - Topix.net

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application with the U.K. Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease . As per the CTA filing, the intended clinical study of ALN-AAT will be performed in normal healthy volunteers, and, then, in subjects with alpha-1 liver disease.

Tags: data application files trial

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Dine and dash couple hit my pizzeria, says owner
15.05Boeing may face criminal prosecution, US says
15.05Indian spices face heat over global safety concerns
15.05'Corrupt ship inspectors demand our food and cargo'
15.05Taylor Swift Eras Tour to boost UK spending by 1bn, says report
15.05Three ways to win the rental property race
15.05Renters in scrum for homes as listing time slashed
14.05Nu Skin Releases 2023 Social Impact and Sustainability Report
More »